1. Introduction
===============

The protease of human immunodeficiency virus type 1 is an essential enzyme in the viral life cycle where it cleaves the viral Gag-Pol polyprotein precursor into Gag proteins and two enzymes, integrase and protease \[[@B1-molecules-18-00236]\]. Inhibition of this enzyme has been used successfully for the treatment of HIV-1-infected patients. Some HIV protease inhibitors, such as saquinavir, indinavir, and ritonavir, have been widely used clinically for the treatment of acquired Immunodeficiency syndrome (AIDS) patients. However, long-term use of these protease inhibitors leads to significant adverse effects and drug resistance. Therefore, it is imperative to find novel HIV-1 protease inhibitors.

Microbial fermentation products are important resources for the discovery of leading compounds with new structure and bioactivity. We are interested in the isolation of new inhibitors of HIV-1 protease, and the microbial products from an actinomycete strain *Streptomyces albosporus* I03A-04862 exhibited promising activity. We found that 1 mg·mL^−1^ of fermentation product (dried powder) from I03A-04862 could inhibit 50.2% of the activity of HIV-1 protease. This strain was classified as a member of the *Streptomyces* genus on the basis of 16S rRNA sequence analysis. A new pentapeptide has been isolated from the fermentation broth of this strain using a combination of Diaion HP-20 macroporous adsorbent resin column, ODS-A and Sephadex LH-20 chromatgraphy and preparative HPLC. Here we report the isolation and structure elucidation of this new compound. We also provide evidence for the demonstration of its inhibitory activity against HIV-1 protease *in vitro*.

2. Results and Discussion
=========================

The compound 4862F ([Figure 1](#molecules-18-00236-f001){ref-type="fig"}) was isolated as a white amorphous powder and its molecular formula was established as C~35~H~53~N~7~O~7~ according to the HR-ESI(+) mass spectra, where the \[M+H\]^+^ ion was observed at *m/z* 684.40954 and \[M+2H\]^2+^ was observed at *m/z* 342.70860 (calcd for C~35~H~54~N~7~O~7~ 684.40847), \[*α*\]^20^~D~ +18° (MeOH, c 0.1).

![The structure of 4862F.](molecules-18-00236-g001){#molecules-18-00236-f001}

The ^13^C-NMR and DEPT spectra of 4862F ([Table 1](#molecules-18-00236-t001){ref-type="table"}) showed a total of 35 carbon signals, consisting of nine methyl groups including three *N*-methyls, three methylenes, fourteen methines, and nine quaternary carbons including five carboxyls. Interpretation of ^1^H, ^13^C, ^1^H-^1^H COSY, HSQC, and HMBC data of 4862F established the amino acid residues as leucine (Leu, 2×), valine (Val), and tyrosine (Tyr). In the HMBC spectrum, the *N*-CH~3~ signal (*δ*~C~ 53.255) showed a cross-peak to the *α*-H signal of Tyr (*δ*~H~ 4.046). The ^1^H-NMR spectra in D~2~O and 2% *d*-TFA showed nine protons (*δ*~H~ 3.128) covered up by the solvent peak when CD~3~OD was used as the solvent, which were correlated to the *N*-CH~3~ signal (δ~C~ 53.255) in the HSQC. This evidence indicates that the N of the Tyr residue was substituted by three methyls. The residue peaks suggests the presence of a histidine (His), which was dehydrated.

The amino acid sequence of 4862F was analyzed using the HMBC correlations ([Table 1](#molecules-18-00236-t001){ref-type="table"}, [Figure 2](#molecules-18-00236-f002){ref-type="fig"}) from relevant *α*-H to neighboring carboxylic carbons. The Leu^1^*α*-H (*δ*~H~ 4.363) signal showed an HMBC correlation to the amide carbon signal of trimethylated-Tyr (*δ*~C~ 166.550), indicating that it is acylated by trimethylated-Tyr. In the HMBC spectrum, the *α*-H signal of Val (*δ*~H~ 4.005) showed a cross-peak to the amide carbon signal of Leu^1^ (*δ*~C~ 172.756), the *α*-H signal of Leu^2^ (*δ*~H~ 4.335) showed a cross-peak to the amide carbon signal of Val (*δ*~C~ 174.520) and the *β*-H signal of the dehydrated-His (*δ*~H~ 4.335) showed a cross-peak to the amide carbon signal of Leu^2^ (*δ*~C~ 174.101). These correlations enabled assignment of the linear sequence for 4862F.
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###### 

NMR Spectroscopic Data of 4862F in CD~3~OD.

  Unit                        Pos.               δC *^a^*, mult.       δH *^b^* (*J* in Hz)          HMBC (H→C)
  --------------------------- ------------------ --------------------- ----------------------------- ------------
  *N*,*N*,*N*-trimethyl-Tyr   CO                 166.550, qC                                         
  *α*                         77.147, CH         4.046, dd(11, 4)      CO, β, 1, N-Me                
  *β*                         32.979, CH~2~      3.139, dd(13, 11)     CO, 1, 2/6, *α*               
                                                 3.257, m *^c^*                                      
  1                           125.257, qC                                                            
  2/6                         116.909, CH        6.967, d(8.5)         β, 3/5, 4                     
  3/5                         131.441, CH        6.642, d(8.5)         1, 4                          
  4                           158.085, qC                                                            
  *N*-Me                      53.255, 3\*CH~3~   3.234, s              *α*                           
  Leu^1^                      CO                 172.756, qC                                         
  *α*                         53.357, CH         4.363, m *^c^*        CO, CO(Tyr), *β*, *γ*         
  *β*                         42.091, CH~2~      1.430, m *^c^*        CO, *α, γ, δ, δ\'*            
  *γ*                         25.918, CH         1.388, m *^c^*        CO, *α, β, δ, δ\'*            
  *δ*                         23.177, CH~3~      0.828, d(6.5)         *α, β, γ, δ\'*                
  *δ'*                        22.319, CH~3~      0.806, d(6)           *α, β, γ, δ*                  
  Val                         CO                 174.520, qC                                         
  *α*                         60.443, CH         4.005, d(8)           CO, CO(Leu^1^), *β, γ, γ\'*   
  *β*                         31.630,CH          1.991, m *^c^*        CO, *α, γ, γ\'*               
  *γ*                         19.623, CH~3~      0.877, m *^c^*        *α, β, γ*                     
  *γ\'*                       19.351, CH~3~      0.916, m *^c^*        *α, β, γ\'*                   
  Leu^2^                      CO                 174.101, qC                                         
  *α*                         54.110, CH         4.335, m *^c^*        CO, CO(Val), *β, γ*           
  *β*                         40.700, CH~2~      1.657, dd(7.5, 7.5)   CO, *α, γ, δ, δ\'*            
  *γ*                         25.681, CH         1.760, m *^c^*        *α, β, δ, δ\'*                
  *δ*                         23.405, CH~3~      0.936, d(7)           *β, γ, δ*                     
  *δ\'*                       21.887, CH~3~      0.884, d(6.5)         *β, γ, δ\'*                   
  (-2 *H*)-His                CO                 166.164, qC                                         
  *α*                         128.992, qC                                                            
  *β*                         119.794, CH        7.409, s              CO, CO(Leu^2^), 1,5, *α*      
  1                           128.745, qC                                                            
  3                           136.069, CH        8.902, s              5, 1                          
  5                           122.783, CH        7.882, s              *β*, 1, 3                     

*^a^* Recorded at 125 MHz. *^b^* Recorded at 500 MHz. *^c^* Multiplicity due to overlapping.

![Selected 2D NMR correlations for 4862F.](molecules-18-00236-g002){#molecules-18-00236-f002}

The whole structure of 4862 F was further confirmed by analysis of ESI-MS/MS spectra ([Figure 3](#molecules-18-00236-f003){ref-type="fig"}). The fragment ion *m/z* 625.16 also confirmed that the *N* of Tyr is trimethylated. The fragment ion *m/z* 531.24 demonstrated that the amino acid residue of the C-terminal is a dehydrated-His.

![ESI-MS/MS data of 4862F.](molecules-18-00236-g003){#molecules-18-00236-f003}

Marfey's method \[[@B2-molecules-18-00236],[@B3-molecules-18-00236]\] was employed to assign the absolute configurations of the amino acid residues resulting from acid hydrolysis of 4862F. The 1-fluoro-2,4-dinitrophenyl-5-L-alanine amide (FDAA) derivatives of the acid hydrolysate of 4862F and the authentic D- and L-amino acids were subjected to HPLC analysis. The absolute configurations of all amino acid residues in 4862F except for trimethylated-Tyr and dehydrated-His were established by comparing their HPLC retention times with those of the corresponding authentic D- and L-standards. The results indicate that all the amino acid residues have L-configuration ([Table 2](#molecules-18-00236-t002){ref-type="table"}).
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###### 

HPLC Analysis of FDAA Derivatized Acid Hydrolysates of Compound 4862F.

  Amino acid   *t*R (min)   *t*R (min) of FDAA derivatized acid hydrolysates of compound 4862F
  ------------ ------------ --------------------------------------------------------------------
  L-Leu        32.335       32.491
  D-Leu        38.252       
  L-Val        26.959       26.527
  D-Val        32.950       

However, the determination of the absolute configuration of the trimethylated-Tyr using Marfey's method and the *Z*, *E*- configuration of the trimethylated-Tyr residue was unsuccessful, because commercial standard materials are not available for these two residues.

To our knowledge, the structure of 4862F has not been previously reported in the literature. The trimethylated-Tyr residue has only been reported in publications a few times, and the dehydrated-His residue has not yet been reported.

Compound 4862F was further tested for the inhibition of HIV-1 protease, and the IC~50~ value is 15.26 nM ([Table 3](#molecules-18-00236-t003){ref-type="table"}) based on an established model used for high-throughput fluorescence detection for HIV-1 protease substrate \[[@B4-molecules-18-00236]\]. As the positive control, indinavir showed IC~50~ values of 4.6 nM. In contrast, 4862F did not show any inhibitory activity against the HIV-1 reverse transcriptase at 200 μg·mL^−1^, indicating the specificity of this compound.
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###### 

Raw data of inhibitory activity of 4862F on HIV-1 protease.

  ------------------------ ------- ------- ------- ------- ------- ------- ------- ------- ------- -------
  Lg (4862F, nM)           3.17    2.87    2.57    2.27    1.95    1.65    1.35    1.05    0.75    0.45
  Mean of inhibition (%)   94.70   93.55   87.25   82.00   73.70   58.95   46.10   49.50   38.35   32.60
  ------------------------ ------- ------- ------- ------- ------- ------- ------- ------- ------- -------

3. Experimental
===============

3.1. General Methods
--------------------

Column chromatography was performed with Diaion HP-20, ODS-A and Sephadex LH-20 (Mitsubishi Chemical Analytech Co., Ltd, Yokkaichi-shi, Mie, Japan). Semi-preparative HPLC was performed using an ODS column (Zorbax SB-C18 column; 5 μm; 9.4 × 250 mm; 2 mL·min^−1^; 280 nm). HPLC analysis was performed using an ODS column (Shimadzu C18 column; 5 μm, 4.6 × 150 mm; 1.0 mL·min^−1^; 280 nm) at 40 °C. ESI-MS data were acquired using a LTQ ORBITRAP XL mass spectrometer (Thermo-Fisher, Waltham, MA, USA). ^1^H-, ^13^C-NMR and DEPT spectra and 2D-NMR were recorded on a Bruker AV500-Ш spectrometer (Bremen, Germany) equipped with a 5 mm PABBO probe head, using TMS as internal standard and chemical shifts were recorded as δ values. The spectra were measured in CD~3~OD, and the chemical shifts were referenced to the residual solvent signal (δ~H~ 4.839, 3.251 and δ~C~ 48.997). ^1^H spectra were also measured in D~2~O and 2% *d*-TFA, and chemical shifts were referenced to the residual solvent signal (δ~H~ 4.800). Optical rotations were measured on a Perkin-Elmer model 343 polarimeter (Waltham, MA, USA).

3.2. Strain
-----------

*Streptomyces*sp*.* I03A-04862 was stored at the China Medicinal Microbiological Culture Collection Center (Institute of Medicinal Biotechnology, Chinese Academy of Medical Sciences and Peking Union Medical College, No. I03A-04862) at −80 °C.

3.3. Fermentation
-----------------

*Streptomyces*sp*.* I03A-04862 was incubated in a rotary shaker (220 rpm) at 28 °C for 48 h in 500 mL Erlenmeyer flasks containing 100 mL medium consisting of glucose 0.5%, yeast extract 0.5%, peptone 0.5%, beef extract 0.5%, corn steep liquor 0.4%, soybean meal 1%, soluble starch 1.0%, CaCO~3~ 0.4%, and CoCl~2~·6H~2~O 0.002% in deionized water (pH 7.2 before sterilization) and then scaled up to 5,000 mL flasks containing 1,000 mL of the medium. The fermentations were carried out at 28 °C for 96 h with aeration and agitation.

3.4. Extraction and Isolution
-----------------------------

The whole fermentation broth (30 L) was filtered to separate into supernatant and mycelia fractions. The mycelia were extracted three times with acetone (3 L). The acetone solution was evaporated under reduced pressure to afford an aqueous solution. The aqueous solution and the supernatant were subjected to Diaion HP-20 macroporous adsorbent resin column chromatography (3 L). A successive elution of the column with H~2~O and 30%, 50%, 75% and 100% acetone in H~2~O yielded five corresponding fractions (HP-0% \~ HP-100%) after removal of solvents. Fractions HP-30% and HP-50% (1 g), with 68.3% inhibitory activity on HIV-1 protease at 1 mg·mL^−1^ were purified by column chromatography using ODS-A (200 mL), and eluted successively with 40%, 50%, 60%, 80% and 100% aqueous methanol solution to yield five corresponding subfractions (ODS-40% \~ ODS-100%) after removal of solvents. The fractions ODS-50% and ODS-60% (93.4 mg, yield 9.3%) with 78.3% inhibitory activity on HIV-1 protease at 1 mg·mL^−1^ were separated by column chromatography using Sephadex LH-20 eluted with water (30.2 mg, dried power, yield 32.3%, with 90.3% inhibitory activity on HIV-1 protease at 1 mg·mL^−1^) and then subjected to reversed phase semi-preparative HPLC twice using a mobile phase of 45% methanol aqueous solution containing 0.1% trifluoroacetic acid (TFA) to yield 4862F (*t*~R~ 19.6 min, 8.5 mg, yield 28.2%, with 99.3% inhibitory activity on HIV-1 protease at 1 mg·mL^−1^).

3.5. Absolute Configuration
---------------------------

Solutions of 4862F (0.5 mg) in 6 N HCl (1.0 mL) were heated at 110 °C for 24 h. Upon removal of excess HCl under vacuum, the hydrolysates were placed in a 1 mL reaction vial and treated with a 1% solution of 1-fluoro-2,4-dinitrophenyl-5-L-alanine amide (FDAA, 150 μL) in acetone, followed by 1 N NaHCO~3~ (40 μL). The reaction mixtures were incubated at 45 °C for 1.5 h, cooled to room temperature, and then acidified with 2 N HCl (20 μL). Similarly, the standard L- and D-amino acids were derivatized separately. The derivatives of the hydrolysates and the standard amino acids were subjected to HPLC analysis using a mobile phase of 45% methanol aqueous solution containing 0.1% trifluoroacetic acid (TFA). The retention times for FDAA derivatives of the hydrolysates and the standard amino acids are summarized in [Table 2](#molecules-18-00236-t002){ref-type="table"}.

3.6. Analysis of the Inhibition of HIV-1 Protease Activity by Compound 4862F
----------------------------------------------------------------------------

The assay method for HIV protease activity measurement is based on intramolecular fluorescence resonance energy transfer (FRET) developed by Edmund \[[@B5-molecules-18-00236]\] and Dong \[[@B4-molecules-18-00236]\]. The assay uses quenched fluorogenic substrates containing a peptide sequence derived from a natural processing site for HIV-1 protease. The quenched fluorogenic substrate (obtained from Sigma, St. Louis, MO, USA) was Arg-Glu (EDANS)-Ser-Gln-Asn-Tyr-Pro-Ile-Val-Gly-Lys-(DABCYL)-Arg, where the fluorescent donor is EDANS and the quenching acceptor is DABCYL. Recombinant HIV-1 protease was expressed in *E. coli* JM109 and purified to homogeneity \[[@B6-molecules-18-00236]\]. Briefly, *E. coli* JM 109 (Novagen, Darmstadt, Germany) were transfected by a p100w plasmid coding for the corresponding enzyme. The insoluble recombinant protein, accumulated in the form of inclusion bodies, was isolated and solubilized in 8 M urea, 10 mM DL-dithiothreitol (DTT), and 20 mM Tris-(hydroxymethyl)-aminomethane (Tris, pH 8.0). The protease was purified by cation exchange chromatography using DEAE-sephacel and CM-cellulose (Sigma). Purified enzymes were stored at −85 °C.

Incubation of recombinant HIV-1 protease with the fluorogenic substrate at 37 °C resulted in specific cleavage of a tyrosine-proline bond, causing an increase in fluorescence due to elimination of intramolecular quenching. In the presence of an inhibitor such as indinavir, the fluorescence signal was expected to decrease as the concentration of inhibitor increased. Thus, inhibition of HIV-1 protease by 4862F in the presence of the fluorogenic substrate was observed as a decrease in fluorescence intensity. The data were obtained with a Polarstar spectrofluorometer (excitation at 340 nm, emission at 490 nm). All values were standardized with blanks. For all of the experiments, the protease was added last to keep the incubation time with inhibitor consistent.

4. Conclusions
==============

A new inhibitor of HIV-1 protease, 4862F, has been isolated from the culture broth of *Streptomyces albosporus* I03A-04862, which was elucidated as *N,N,N-*(trimethylated)-Tyr-L-Leu-L-Val-L-Leu-(dehydrated)-His. This compound displayed inhibitory activity against HIV-1 protease, with a IC~50~ value of 15.26 nM using a fluorescence-based assay.
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